Get started

Covid19stock

KNR -- Oversold; Double Bottom at .89. On watch for a bounce.KNR has been beaten down but looks way overdone, given they have just raised $8.5 at 1.50 with institutional investors. The company reported respectable $3.3M revenues in Q1 2021. Their BioCloud COVID-19 detection device will be used by the Canadian Olympic delegation at the Tokyo Olympics. The US sales channel is being worked on. Insiders are buying in the open market. Share buyback program is in effect. Bullish MACD divergence on the chart.
NEO:KNRLong
by wealth_bakery
1
UPI -- Fundamentally undervalued; multi-bagger candidate!UPI is ridiculously undervalued at $15M mkt cap and is a potential multi-bagger candidate from these levels. - Close to $10M in revenue in 2020 and is on pace to at least double it — recorded $1M in sales in the first week of June! - Profitable, no debt - Exclusive distributor of the 20-second non-invasive (finger scan) COVID-19 test that is currently undergoing clinical trial at Toronto Pearson Airport and could be a game changer! - Other products include COVID-19 virus elimination tech using UV lights, thermal detection and air filtration - Expanding to the US - Insiders are buying in the open market
ULong
by wealth_bakery
ALNOV NOVACYT Novacyt big fall today, don't worry medium long term still hasn't broken level but keep an eye out for volatility next week we recommend that you buy if you can to the level you think is appropriate, it is a company that in the medium term has high expectations L.E.D Capital Management has investments and has had large investments in ALNOV, continuing to rely on its potential - THIS IS NOT A FINANCIAL ADVICE AT ALL- Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying an extensive range assays and reagents worldwide. HE'S GOT BIG CONTRACTS FOR COVID TESTING. A cordial greeting good investment. In Spain at 9/04/2021 carefully L.E.D
EURONEXT:ALNOVLong
by wallstreetstocks
Whats next for Genedrive #GDRI have a few possibilities now for #GDR, I know it looks great, up down or sideways. But really these are now roughly the options with the clearly communicated uncertainty and market reaction. First of all the original count and targets are still intact, in green, we are in a C wave or next impulse W3, and we have done a wave 1 and 2, still up we go from here. We need volume and clear impulse to move and prove this is the case in the next days/weeks ahead. This plan can alter depending on the intensity of the impulses, can truncate to an ending diagonal C wave with lower 5th wave targets, probably at the £3 mark at the end, or can extend as a higher high W3 into much higher W5 target than currently pictured. All depends on newsflow. The next two blue and orange options are based on the count that we have a failed impulse X wave instead of a wave 1 of the C. Hence the gap in price overreaction and massive sell out that is remarkable in volume. Any trader would sell off at the next possible gap approach if they had no SL in place and were not part of that sucker -50% SL fill. So following the X wave we do a Y in some kind of a triangle (blue) which shows quite a bullish response for the short term (another hype of expectations?). The orange squiggle is a possibility on a short term bad news (further delay or funding needs) to put a lower low and fill in that lower demand zone under 30p before turning into the upside. Not hard to imagine fundamentals supporting any of these setups and also that all these interim plays the SP could be going towards the previous or a new high when the dust settles. I still support long term holding if you can achieve a healthy average level. The blue squiggle is my favourite, although purely the volume pattern suggests the orange to play out - Now one thing about volume, is that when PIs pump up something based on rumours and hype without any substance, and with the level of PI allocation to this stock, there is no surprise it will fall big volume on unexperienced PI fear. The lack of II support on the SP volume is remarkable, therefore you cant really apply those volume triggers as you would normally do seeking for II activity. CEO comments were spot on to that. Leave the hype of expectations to the company based on their substantial news. imo of course and dyor
GLong
by tempertrade
11
HGEN: Weekend Before Phase III DataHGEN has two RCTs with imminent data, one of them the company's own, the other the NIH's ACTIV-5 Trial. The company is preparing to file an EUA for Lenzilumab pending the trials' completion. Announcements are expected in the week starting March 29, two days from now. Nomis Bay, a fund that had held a large stake of HGEN since it was trading in single digits unloaded millions of shares in the weeks leading up to now. The fund still holds between 9% and 10% of the outstanding shares.In conferences throughout March, HGEN executives mainly showcased the potential for Lenz as a COVID therapeutic, and differences between their trial designs and those of other, failed monoclonal antibodies. I hope everyone is sized appropriately, whether long or short. This stock could make some very large moves soon.
HLong
by decaro
Dyadic and Medytox To Develop Vaccines Against COVID-19 VariantsDyadic and Medytox To Develop Vaccines Against COVID-19 Variants Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19 vaccines) Exclusive license for Republic of Korea and multiple Southeast Asian countries, if successful Manufacturing protocols to produce vaccines from C1 have been successfully transferred and reproduced at Medytox finance.yahoo.com
NASDAQ:DYAI
by AlenCiken
$SPCB Wins COVID-19 Quarantine Project $3 Million per MonthSuperCom Wins COVID-19 Quarantine Compliance Project with the Israeli Government Valued at an Estimated $3 Million per Month in Recurring Revenues Initial project term of 3 months, with potential extension for up to 36 months This nationwide project is expected to commence next week, along with contract signing, for an initial term of 3 months, with an option to be extended for up to 36 months. The project is billed at a per-unit per-day rate is expected to generate approximately $3 million per month in recurring revenues for SuperCom. However, revenue may increase or decrease based on actual usage. finance.yahoo.com
NASDAQ:SPCB
by AlenCiken
CHWY: The Covid Re-Opening Is Not Going To Stock This Tail WagChewy has taken a breather since it hit it's ATHs in mid Feb. This is a secular drawdown due to the recent rise in rates that has hit all high growth stocks. There is also a perception on this name that it is a "Covid Play" and that it won't continue to gain market share and grow at the same rate during Covid. Yes- CHWY did get incremental growth from Covid lockdowns, however new pet owners who have always used CHWY are not going to start going into Petco to get their food, toys, medicine and other pet related items. They will stay with CHWY. I think CHWY has developed a strong support level at ~$100 and any dips below that should be bought. I am tracking an $97 support level as well from it's low to start the year. If it broke that $87 level I would re-evaluate the situation. My 6-Month PT is $125.
NYSE:CHWYLong
by RobertTheTrader
HALBERD CORPORATION· Current Price – $0.0419 · Best Case Scenario PT over 1$ · Market Cap – $11 million · Debt – 0 Halbert Corporation Are a biomedical company with a clear aim to revolutionize the world of medicine. They are working towards a creation of variety of antibodies and treatments using extracorporeal techniques (outside of body). They believe they have the technology to cure diseases like, Covid-19, PTSD, Cancer, CTE, tuberculosis, malaria, strokes and heart attacks, blood sepsis, Alzheimer’s Disease. In the last 8 months they have secured 7 provisional patents (which give the global rights) to technology of treating severe Covid-19 patients, Covid-19 nasal spray, antibody cocktail to boost immune system against Covid - 19 and recently developed two new antibodies that no other big pharma has, which allows them detect Covid-19 in matter of minutes using saliva or blood samples. Furthermore, are working with $GRPS to develop anti-addiction patches (alcohol, drugs, nicotine). To achieve their further goals they have carefully selected to partner with Arizona State University (who have won the first place in innovation for the last 6 years going in the USA, higher than MIT or Stanford). This partnership has already delivered amazing milestones and they are already working towards filing for new joint provisional patents. Halbert has 0 debt, yes ZERO and been receiving funding in 2 million chunk donations due to promising results. Halberd’s corporate charter also prohibits them from issuing any kind of convertible financial instrument, debt or preferred stock, however the corporation shall be able to issue warrants or options. Management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment. Furthermore, the ultimate catalyst, which seems quite likely is for Halbert to partner or licence their technology to one of the big pharma as the CEO, William has mentioned so on multiple occasions. In the past, he has been approached by the big pharma (Pfizer and Novartis), and hopes the same will happen with their revolutionary technology. Issued Patents 2014 - Sequential Extracorporeal Treatment of Bodily Fluids 2015 - Utilization of Stents for the Treatment of Blood Borne Carcinomas Provisional Patents 11/2020 - Fluorescent Antibody’s in Covid-19 Detection & Treatment 10/2020 - Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus). 10/2020 - Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus 09/2020 - Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans 04/2020 - Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus 04/2020 - Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients 03/2020 - Method for Treating and Curing Covid-19 Infection Future Patents During podcasts and interviews the CEO said he will announce another 2 patents soon. They are waiting to achieve provisional status to ensure the technology is safe. Further patents are in the pipeline as CEO’s devised a strategy to secure as many patents as they can, of which they could then either licence or partner on developing on joint ventures with big pharma. Upcoming Catalyst 2021 · 2 patent provisional applications yet to be announced · Development of antibody cocktail vitamins to boost immune system against Covid-19 (Q2 launch and start to generate revenue) · Development of Covid-19 Nasal Spray · Commercial development of Covid-19 test using saliva or blood (takes only a minute no nasal swap which is uncomfortable) · Patent Licencing to other pharma companies – they produced antibodies that are stronger than some of the big pharma · Partnerships and joint ventures with other organizations · Discovery of new treatments and patent fillings · Further development of extracorporeal technology to treat cancer, PTSD, Alzheimer’s, blood sepsis, CTE · Anti-addiction patches Sociability Factor In penny stock market, especially during current times (rise of social media and social traders) the CEO’s or the organization being sociable, sharing achievements, milestones, ethos and so on can have a massive impact on the share value. In this regard, Halberd’s corporation in my view would score high points. They tend to release anywhere between 2/5 press releases a month in which various milestones would be announced via text, video interviews or podcasts. Senior Leadership Team The CEO’s aim was to ensure that they develop a very cohesive team of talented people to achieve greatness. Here below I have listed a few KEY members including bio snapshots. Business Advisory Board The CEO – based on the videos and podcasts that are available (6+) of William A. Hartman sounds very ambitious and driven on a mission to be the best in the industry and revolutionize medicine. He believes Halberd corporation share value should be worth $1 per share. This may sound like very ambitious venture for some, however, let us not forget he founded and headed separate business group within TRW Automotive with plants in the U.S., Mexico and Europe that produced combined annual sales of $1.3 Billion – this shows extreme capability. He has also worked as COO for Nanologix, Inc, President and CEO of Premier Biomedical. I would recommend checking out any of his interviews to feel his passion. Carl Eller - retired NFL Pro Football Hall of Famer, and President of the NFL Retired Players Association, was drafted in 1964 as the league’s 6th pick overall by the Minnesota Vikings, he became a major factor as a defensive end with the unit known as the “Purple People Eaters.” Eller became a six-time Pro Bowl player who appeared in four Superbowls and is currently focused on helping former players transition into retirement. Alec Torelli - is an entrepreneur, author, motivational speaker and professional poker player who has worked with various companies to apply his life experiences/lessons from poker, in a practical manner, to carry out their corporate visions, increase sales and/or improve service delivery while creating meaningful lives for their employees. Scientific Advisory Board Mitchell S. Felder, MD - is a prolific inventor. He is a Board Certified Neurologist and former CEO, President, Chairman and founder of Infectech and Nanologix, and currently serves as Locum Tenens Attending Neurologist with UPMC Pennsylvania Dr. Felder has authored or co-authored six publications, three studies and has currently 21 issued patents. Dr. Felder was the Acting Chief of the Department of Neurology, Sharon Regional Health System from 1989 until 2001. Dr. Felder served as the Acting Chief of the Department of Neurology at the William Beaumont Army Medical Center in 2011. Dr. Qiang (Shawn) Chen, who is the Principal Investigator at ASU, in charge of the research and development for Halberd Corp: Take a look at his research projects over the last 4-5 years and you see why this HALB/ASU cooperation is a marriage made in heaven. Only weeks ago, Halberd signed another R&D-agreement with GreenBioAZ inc, it's a start up from Arizona State University and will do research for Halberd's radiofrequency technology. Dr. Chen is CEO of GreenBioAZ Patricio Reyes, MD, FAAN - a board certified neurologist and neuropathologist, and Chief of Neurology/TBI/Alzheimer’s Disease/Cognitive Disorders at the VA Medical Center in Phoenix, Arizona and is a Board Member of the Retired National Football League Players Association. Dr. Reyes is a board member, and former Chair of the Education Committee and 2009 Distinguished Educator of the Association of Ringside Physicians. HALB has access to the VA Hospital Group because of Dr. Reyes. Timeline of Key Press Releases I have gone through the list of all of their press releases (they post regularly) and compiled key updates here below: April 6, 2020 - Halberd announces agreement to retire 192,000,000 outstanding common shares and reduced authorized shares of common stock to 1,000,000,000. April 8, 2020 – Halberd, Premier Biomedical ($BIEI) and Gold River Productions ($GRPS) announce the signing of a multi-faceted agreement for ongoing R&D into a potential treatment and cure for Covid-19 as well as development of Premier’s Anti-Addiction Patch. July 1, 2020 - Halberd establishes United Kingdom subsidiary to facilitate access to European research facilities and markets to establish a global footprint. July 13, 2020 - Halberd’s corporate charter prohibits it from issuing any kind of convertible financial instrument, debt, or preferred stock. August 4, 2020 - Halberd secures $2 Million for Covid-19 Research August 31, 2020 - Halberd signed an agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments. September 21, 2020 - Covid-19 Research Program Progress – Successful Covid Spike Protein Disease Antigen September 24, 2020 - Successful creation of a fluorescent antibody, that will help them create a rapid Covid-19 test using saliva or a drop of blood. This approach will allow for accurate test results in a matter of minutes – believe travel industry may benefit from this approach. October 8th, 2020 – CEO’s letter of updates and accomplishments October 13, 2020 – Halberd and ASU Develop Antibody Against Covid-19, pursuing new joint patent. October 19, 2020 – in process to filing a new joint patent with AUS for creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19. This protein will allow extremely rapid identification of the Covid-19 virus in nasal mucus, saliva, and blood. October 29, 2020 – Strategic plan curing blood sepsis, Alzheimer’s Disease, Heart Attack and Stroke using extracorporeal process November 12, 2020 – Patent pending for Covid-19 detection test from saliva or blood in minutes. December 1, 2020 – Halberd re-organizes advisory board. December 17, 2020 - Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19 December 23, 2020 - Halberd Produces a Second Monoclonal Antibody Against Covid-19 Spike Protein – “Mathematically speaking, if each is 90% effective independently, then, absent any interrelationship of the two applications, the combination should be 99% effective. In other words, the prospect of obtaining diagnostic test false positives or false negatives is substantially reduced when antibodies work in tandem” January 4, 2021 - Halberd Corporation 2020 Year End CEO Letter, looking forward to 2021 January 14, 2021 - Halberd Develops Medication to Boost Immune System Against Covid-19 February 16, 2021 - Halberd has engaged GreenBioAZ to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease. March 2, 2021 - Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater - “We are excited about the progress being made in developing Halberd’s effective proprietary antibodies against Covid-19. These results put our antibody in the same realm of effectiveness as the best-known competitive SARS-COV-2 antibodies. Since posting links may take an excessive amount of space here, you can find all the press releases here and search by date, plenty more to see that are not included in my post - Hope people found this helpful and I look forward to seeing what the future holds for $HALB!
OTC:HALBLong
by headdeveloper33
1
Strong pan-coronavirus effectiveness of clinical drug candidatesPan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application $NNVC reported yesterday on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is preparing a pre-IND application. NV-CoV-2 is the Company's broad-spectrum anti-coronavirus clinical lead drug candidate for the treatment of COVID-19 patients based on its nanoviricides® platform. $NNVC is also developing NV-CoV-2-R, a drug treatment that combines the power of both NV-CoV-2 and remdesivir in a single drug that encapsulates and protects remdesivir inside NV-CoV-2. Both NV-CoV-2 and NV-CoV-2-R are expected to work against most, if not all , coronaviruses and their variants, based on the Company's findings on their pre-clinical effectiveness discussed below. NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison to remdesivir against two distinctly different coronaviruses in our new cell culture studies leading towards a pre-IND application and thereafter an IND submission for these COVID-19 drug candidates. The Company intends to report on the results of these studies in its pre-IND application to the US FDA to obtain guidance regarding human clinical trials for treatment of COVID-19 patients. Additionally, the Company is actively seeking opportunities to engage appropriate sites for human clinical trials. Further, the Company is engaged in the preparation of clinical trial protocols and other activities that would be necessary for submitting an IND application to the US FDA. The Company has developed NV-CoV-2 based on its platform nanoviricides® technology. This approach enables rapid development of new drugs against a number of different viruses. finance.yahoo.com
AMEX:NNVC
by AlenCiken
2
SONA NANOTECHDowntrend broken. Bullish flag on the 1 hour while trading tight with the 9 EMA. Above average volume past 2 days with no news? Leak ? This play is known for it's volatility and leaky news, market is expecting good update about the company's new Covid-19 saliva test, along with sales, revenue projections, and regulatory approvals. Either one of those will increase the sp drastically. If all goes well, I really see this play breaking it's previous ATH of $16, but for now remain cautiously optimistic. Short term goal is $8, can change depending on what the company releases. Drop your targets below or what news you think we will hear next. Long on SONA.CN
CSE:SONALong
by SamView2920
$JAN to Sell its Legacy Recycling Business for $25 MillionJanOne Announces Definitive Agreement to Sell its Legacy Recycling Business for $25 Million Successful disposition will facilitate continued strategic focus on high-value late-stage biopharma asset JAN101 for the treatment of peripheral artery disease (PAD) The transaction is expected to close on or before August 18, 2021 JanOne recently completed production of JAN101 under Current Good Manufacturing Practices (cGMP) for the anticipated Phase 2b PAD trials. The Company plans to submit the Phase 2b protocol and related documents to the FDA under its Investigational New Drug Application (IND) for PAD in March 2021 . finance.yahoo.com
J
by AlenCiken
Reduced recovery time in mild-to-moderate COVID-19 patientsNew Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients New Phase 3 study results show added nutritional protocol reduces recovery time in mild-to-moderate COVID-19 patients The addition of the nutritional protocol, or combined metabolic activators (CMA), to the Turkish standard of care not only reduced recovery time but improved liver health and decreased levels of inflammatory markers. finance.yahoo.com
NASDAQ:CDXC
by AlenCiken
TSF -- Official Contact Tracing partner of Boston Bruins/CelticsMassive news from TraceSafe -- announcing a partnership today with TD Garden, home of the Boston Bruins and the Boston Celtics. The company is in conversations with multiple other sports franchises around the world and has a footprint in Singapore, India, Hong Kong, US and Canada. Already generating more revenue than competition that is trading at 10x or more valuation. MTRX.V has $240M+ mkt cap, FD.V $1.5B vs TSF's $26M. Likely multi-bagger from current levels.
TLong
by wealth_bakery
UPI.V - Breakout. 1-min rapid COVID-19 tests and much more.UPI is a fundamentally strong company with $10M in year revs and only $22M mkt cap. They're selling various COVID-19 detection tech and are also in air sanitation business. Today's news adds to their portfolio nicely: Universal PropTech Inc. Invests in and Secures defined Agency Rights for ISBRG Corp.'s SpotLight-19(C) Technology Designed to Detect Covid-19 Non-Invasively in Under One Minute Toronto, Ontario--(Newsfile Corp. - February 18, 2021) - Universal PropTech Inc. (TSXV: UPI) ("UPI" or the "Company") is pleased to announce that it has completed an investment in ISBRG Corp. ("ISBRG") for a minority interest, and secured agency rights to their SpotLight-19© Technology. ISBRG is a data analytics company which has developed the SpotLight technology platform designed to generate comprehensive health care data non-invasively within seconds at a nominal incremental cost per test. SpotLight-19© is non-invasive, and ISBRG is undertaking trials to determine efficacy in detecting Covid-19. In addition to its minority investment, UPI will act as the exclusive sales agent for the SpotLight-19© technology and other future platform offerings for the government and education sectors in Canada.
U
by wealth_bakery
ALDR Delta Drone Created in 2011, Delta Drone is a leading international player in the field of civilian drones for professional use. The group designs and commercialize a range of professional solutions. In addition, it provides support services which represent a complete chain of value. This penny company seems very attractive to us, it is listed on the Paris Europe Stock Exchange. If you have any questions. Let me know what you think in the comments A cordial greeting L.E.D. In Spain at 16/02/2021
A
by wallstreetstocks